Versions Compared

Old Version 26

changes.mady.by.user Lauren White

Saved on

compared with

New Version 27

changes.mady.by.user Lauren White

Saved on

Key

  • This line was added.
  • This line was removed.
  • Formatting was changed.


Project Scope

  • Define role of QTLs in QbD, in particular the relationship to CTQs (Critical to Quality Factors), Estimands and continuous quality improvement (CQI)
  • Discuss the use of QTLs in Early Development/small studies, bio equivalence and complex designs
  • Discuss examples of how to define QTLs, different methodologies and different parameters in use across the industry
  • Discuss difficulties and challenges of implementation of QTLs
  • Examine role of QTLs as part of the of the lessons learned (RCA) feedback loop



Project LeadsEmail
Andy Lawtonw.a.lawton@aol.co.uk
Chris Wellschris.wells.cw1@roche.com
Wendy Dobson (PHUSE Project Manager)

wendy@phuse.global



Project MembersOrganisation
Adam Czernik Janssen Research and Development
Andrew McGowanRHO World
Andrzej KinasiewiczAstraZeneca
Anne LawrenceAbbVie
Crupa KurienPfizer
Heather TurnerPrism
Heidi HoffmanRocheGenentech
Julie AppelNovo Nordisk
Kate TomlinsonPRISM
Linda Del PaggioRocheGenentech
Mary ArnouldAstellas



Project MembersOrganisation
Michael WalegaBMS
Mireille LovejoyRoche
Monika MoerschBoehringer-Ingelheim
Mukesh BabuIndustry
Nick Wells Syneos Health 
Paul BrownDanish Medicines Agency
Priti GuptaIndustry
Sheetal ChandaranaRoche
Steve Young CluePoints
Steven GilbertPfizer
Sukalpo SahaTCS/Roche



Objectives & DeliverablesTimelines
PublicationsQ42021
White PaperQ22022



Status
colourBlue
titleCurrent Status
 Q22021

This is a new project and is actively seeking participation. If you are interested in joining this team, please email workinggroups@phuse.global.



Problem Statement

QTLs -  the role they play in defining quality within the QbD framework, their relationship to Critical to Quality factors, associated methodologies and the interpretation of them have not been fully defined in clinical development, in particular where early development/small studies, bio equivalence studies and complex designs are concerned.

Problem Impact

This will impact the whole clinical development process and allow the move away from perfection to a defined and achievable quality, from which continuous quality improvement can begin.



Terminology Example:

  • Target Product Profile (TPP)
    • Patient wants extended dosing from current BD product on market
  • Critical Quality Attribute (CQA)
    • Once a day dosing
  • Critical to Quality Factor (CTQ)
    • In early stage trials drug levels shown at 24 hours
    • In Phase 2-3 demonstrate efficacy
  • Quality Tolerance Limit
    • Pre-define what will be acceptable limits for acceptance
      • These QTL's will change at different stages